fig3

IL-32 as a prognostic biomarker and therapeutic target in glioma: implications for tumor progression and immune modulation

Figure 3. Functional enrichment analysis of IL-32 in glioma. We performed differential expression analysis by comparing high and low IL-32 expression glioma samples. Across three independent glioma cohorts, genes significantly elevated in the high IL-32 expression group were subjected to GO and KEGG pathway enrichment analyses: (A) TCGA, (B) CGGA, and (C) REMBRANDT. IL-32: Interleukin-32; GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; TCGA: The Cancer Genome Atlas; CGGA: Chinese Glioma Genome Atlas; TNF: tumor necrosis factor; ECM: extracellular matrix.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/